Major and complete cytogenetic responses at 3, 6, and 9 months on different regimens
| Regimen . | No. of patients . | % cytogenetic response, complete/major . | ||
|---|---|---|---|---|
| 3 mo . | 6 mo . | 9 mo . | ||
| Imatinib mesylate for early chronic-phase CML | 50 | 34/74 | 52/80 | 60/77 |
| IFN-α | 274 | 4/2 | 3/11 | 5/14 |
| IFN-α + cytarabine | 257 | 1/9 | 7/23 | 8/23 |
| IFN-α + cytarabine + HHT | 90 | 4/24 | 7/28 | 11/30 |
| Imatinib mesylate for chronic phase after IFN-α failure (M. D. Anderson study group)26 | 261 | 26/44 | 31/49 | 35/53 |
| Regimen . | No. of patients . | % cytogenetic response, complete/major . | ||
|---|---|---|---|---|
| 3 mo . | 6 mo . | 9 mo . | ||
| Imatinib mesylate for early chronic-phase CML | 50 | 34/74 | 52/80 | 60/77 |
| IFN-α | 274 | 4/2 | 3/11 | 5/14 |
| IFN-α + cytarabine | 257 | 1/9 | 7/23 | 8/23 |
| IFN-α + cytarabine + HHT | 90 | 4/24 | 7/28 | 11/30 |
| Imatinib mesylate for chronic phase after IFN-α failure (M. D. Anderson study group)26 | 261 | 26/44 | 31/49 | 35/53 |